This is a population that previously felt stigmatized by health care providers and often didn't return. But now that they're actually seeing themselves get healthier, asking clinicians questions and engaging more, I do think we're seeing new patients.
The impact of the drugs on overall healthcare use is not yet clear. The new diagnoses could mean higher initial spending, but early detection could save costs down the line.
Many overweight patients avoid doctors and routine tests for years due to the stigma and bias they often encounter. A lot of them are now starting to engage.
Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound and Mounjaro have been shown to lead to average weight loss of at least 15%.
Collection
[
|
...
]